Healthcare Equipment and Supplies
Company Overview of Sequent Medical, Inc.
Sequent Medical, Inc., a medical device company, develops catheter-based devices for neurovascular specialists and their patients. The company develops WEB Aneurysm Embolization System, a platform that advances therapeutic options for ruptured and un-ruptured cerebral aneurysms. It serves customers in Europe and other countries. Sequent Medical, Inc. was incorporated in 2006 and is based in Aliso Viejo, California with operations in Bonn, Germany.
Aliso Viejo, CA 92656
Founded in 2006
Key Executives for Sequent Medical, Inc.
Chief Executive Officer, President and Director
Founder, Chief Technology Officer, Vice President and Director
Chief Financial Officer and Vice President
Vice President of Quality Assurance & Regulatory Compliance
Compensation as of Fiscal Year 2015.
Sequent Medical, Inc. Key Developments
Sequent Medical Announces Approval to Utilize Latest Generation WEB Devices in U.S. IDE Study
Feb 12 15
Sequent Medical announced that the U.S. Food and Drug Administration has approved the inclusion of the SL ("Single Layer") family of WEBTM Aneurysm Embolization Device devices for use in its U.S. Investigational Device Exemption ("IDE") clinical study called WEB-IT. Patient enrollments in WEB-IT have already been completed utilizing the SL family. Compared to previous versions of the WEB device family, the SL family offers a lower delivery profile, improved navigability, and enhanced visualization. The SL configurations are made possible by further advancement of Sequent Medical's proprietary MicroBraid TM technology. The SL family consists of two separate product configurations, the WEB SL and WEB SLS, each with a distinct shape designed to accommodate varying aneurysm morphologies.
Sequent Medical, Inc. Announces Prospective Clinical Data on Web Aneurysm Embolization System
Sep 8 14
Sequent Medical, Inc. announced the presentation of results from WEBCAST, a prospective study of the WEB Aneurysm Embolization System at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress. The study examined safety and aneurysm occlusion rates in 51 patients with complex wide neck bifurcation aneurysms treated with the WEB across ten European centers. The study met the primary efficacy endpoint demonstrating 85.4% adequate and stable occlusion without retreatment at six months follow-up. The study also demonstrated good safety at thirty days and six months, with 0% procedure-related morbidity and mortality. These encouraging results add to a growing body of clinical evidence for the WEB including the recently initiated WEB-IT Investigational Device Exemption study in the United States, two ongoing European prospective, multicenter studies fifteen peer-reviewed clinical publications, and nearly 1,000 patients treated with the WEB.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries